News

Under the terms of the new agreement, NascaCell receives non-exclusive rights to uses of aptamers for target validation, mode of action studies, drug discovery, and aptamer structure-based drug

CST’s PhosphoScan proteomics technology is a patented methodology that enables the discovery of drug target phospho-profiles (PhosphoSignatures) in cells and disease tissues. In the current research project, PhosphoScan

NeutroPhase is a dilute solution of hypochlorous acid, which is rapid-acting in saline with broad-spectrum antimicrobial properties. In September 2007, NovaBay received 510(K) approval from the US Food

The adverse effects were found in FDA-approved and nonapproved usages. The most severe adverse effects were found in children treated for spasticity in their limbs associated with cerebral

Retigabine demonstrated statistically significant results on the primary efficacy endpoints important for regulatory review by both the FDA and the European Medicines Evaluation Agency (EMEA). Restore 1 evaluated

The Avado study (BO17708) investigated the addition of Avastin administered either at 15mg/kg or 7.5mg/kg every three weeks to docetaxel chemotherapy. Both doses of Avastin in combination with

The 160-subject study, part of an extensive Phase II program for the vaccine, measured the immune response to the vaccine patch, which is approximately the size and shape

As an affiliate partner, LLUMC, has agreed to utilize exclusively Amerinet’s national portfolio of product and service contracts and Total Spend Management business intelligence solutions to assist in

Upon consummation of the merger, Dara became a wholly-owned subsidiary of Point, and Point changed its name to Dara BioSciences. Additionally, the board of directors and executive officers